Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:50:11 EDT Tue 19 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:SUPN - SUPERNUS PHARMACEUTICALS INC - https://www.supernus.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SUPN - Q3.947.50·59.662.547.62-0.71-1.5591.527,6758,53148.38  48.53  47.5259.68  30.8316:48:37May 0615 min RT 2¢

Recent Trades - Last 10 of 8531
Time ETExPriceChangeVolume
16:48:37Q47.62-0.718,288
16:36:43Q47.62-0.7161
16:10:04Q47.62-0.711
16:10:04Q47.62-0.711
16:10:04Q47.62-0.711
16:10:04Q47.62-0.711
16:05:22Q47.50-0.831
16:04:11Q47.62-0.711
16:04:09Q47.62-0.711
16:04:04Q47.62-0.711

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-06 17:01U:SUPNNews ReleaseSupernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
2026-05-05 16:05U:SUPNNews ReleaseSupernus Announces First Quarter 2026 Financial Results
2026-04-22 16:15U:SUPNNews ReleaseSupernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
2026-02-24 16:05U:SUPNNews ReleaseSupernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
2026-02-23 18:15U:SUPNNews ReleaseSupernus Pharmaceuticals to Participate in March Investor Conferences
2026-02-12 16:35U:SUPNNews ReleaseSupernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
2025-12-03 16:05U:SUPNNews ReleaseSupernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
2025-11-21 16:06U:SUPNNews ReleaseSupernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
2025-11-12 16:05U:SUPNNews ReleaseSupernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
2025-11-04 16:01U:SUPNNews ReleaseSupernus Announces Third Quarter 2025 Financial Results
2025-10-21 17:00U:SUPNNews ReleaseSupernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
2025-09-17 16:30U:SUPNNews ReleaseBiogen Receives European Commission Approval for ZURZUVAE(TM) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
2025-08-27 16:15U:SUPNNews ReleaseSupernus Pharmaceuticals to Participate in September Investor Conferences
2025-07-31 08:44U:SUPNNews ReleaseSupernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
2025-07-28 08:25U:SUPNNews ReleaseSupernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
2025-07-22 16:30U:SUPNNews ReleaseSupernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
2025-06-16 07:00U:SUPNNews ReleaseSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
2025-05-29 08:31U:SUPNNews ReleaseJay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree(TM) Content Series with Supernus Pharmaceuticals
2025-05-28 16:06U:SUPNNews ReleaseSupernus Announces Paragraph IV ANDA Filings for Qelbree(TM)
2025-05-28 16:05U:SUPNNews ReleaseSupernus to Participate in the 2025 Jefferies Global Healthcare Conference